Enterprise Value

717.6M

Cash

7.014M

Avg Qtr Burn

-6.556M

Short % of Float

0.05%

Insider Ownership

0.00%

Institutional Own.

6.70%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Aemcolo® (rifamycin) Details
Diarrhea caused by non-invasive strains of Escherichia coli (E.coli)

Approved

Quarterly sales

Movantik® (naloxegol) Details
Pain, Constipation, Biliary atresia, Liver disease

Approved

Quarterly sales

Approved

Quarterly sales

RHB-102 (Bekinda®) Details
Digestive tract, Stomach, Intestinal infection

Phase 3

Update

RHB-104 Details
Inflammatory disease, Crohns disease

Phase 3

Update

RHB-102 (Bekinda®) Details
Irritable bowel syndrome, Bowel disorder, Post-traumatic stress disorder, Psychiatric disorder

Phase 3

Initiation

Phase 2

Data readout

Failed

Discontinued

RHB-106 Details
Bowel preparation , Breast cancer

Failed

Discontinued

RHB-204 Details
Bacterial infection

Failed

Discontinued